A Phase 1, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients With Advanced Malignancies

Inclusion Criteria:

- Advanced solid malignancy or non-Hodgkin’s lymphoma that is refractory to treatment
or has recurred

- Age > 18 years

- Adequate hematologic (blood), kidney and liver function

- Negative pregnancy test (females of childbearing potential only)

- Willingness to use effective contraception by both males and females throughout the
treatment period and for at least 2 months following treatment.

Exclusion Criteria:

- Any chemotherapy or radiation within the past 4 weeks

- Symptomatic or uncontrolled brain metastases (patients with history of brain
metastases who have had repeat brain scans within the past 30 days that demonstrate
no evidence of tumor progression or brain swelling and who do not require
corticosteriod treatment may be eligible)

- Significant cardiovascular illness including, but not limited to, the following:
active infection, uncontrolled hypertension, symptomatic congestive heart failure,
unstable angina pectoris, heart attack within the past six months, or uncontrolled,
irregular heart beat

- Inadequate cardiac function

- Prior investigational therapy within the past 28 days

- Pregnant or breast feeding women